Additional Context: Announced May 30, 2025, the terminations end funding that had run from 2005 for the two consortia based at Scripps Research and Duke University. According to AVAC, with only one more year of funding before the grants end, current plans for research, clinical trials and progress toward a vaccine are all at risk.

Devex Researcher Note: The U.S. accounted for nearly 90% of global HIV vaccine research funding annually. The withdrawal has direct international consequences — including for clinical trial programs in African countries where researchers had been preparing to test CHAVD-designed vaccines in populations most affected by the HIV epidemic. The CHAVD cuts are part of a broader pattern of U.S. HIV funding reductions in 2025, collectively threatening decades of global progress against HIV.

Source: AVAC